Q32 Bio Inc. growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue: —
EBITDA: +154.8%
EBIT: +133.7%
EPS: +154.3%
Free cash flow: +58.3%
Operating cash flow: +58.3%

Forward estimates

Revenue: —
EBITDA: —
EPS: —

Three-year CAGR

Revenue: +100.7%
EBITDA: +169.1%
EBIT: +125.6%
Net income: +162.5%
EPS: +147.3%
Free cash flow: +50.5%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.